COPPELL, Texas--(BUSINESS WIRE)--Aug. 10, 2015--
Mannatech,
Incorporated (NASDAQ: MTEX),
the founder of the M5MSM
(Mission 5 MillionSM) social entrepreneurial movement,
the pioneer of nutritional glycobiology and the global innovator of
naturally sourced supplements based on Real
Food Technology® solutions, announced that it will
release a limited supply of Manapol powder, which will be exclusively
available in the U.S. on August 19.
Manapol is a pure, premium, 100 percent aloe vera gel extract, designed
to support cell-to-cell communication.* Mannatech’s offering has a
guaranteed molecular weight of more than one million Daltons1,
testing the highest of any other aloe gel extract available in the world
today. Rich in acetylated mannans found in the inner leaf gel of the
aloe, this product supports the body’s immune system and may also
provide gastrointestinal benefits.*
For more than 20 years, Manapol has been a key ingredient in many
Mannatech products such as Advanced
Ambrotose® and Ambrotose
complex, and is finally being released as a standalone product after
years of requests.
Manapol powder will be launching exclusively for Associate attendees of
the Los Angeles Super Regional meeting, August 14-15, 2015. The official
launch for all other U.S. Mannatech Associates and the general public
will be on Wednesday, August 19.
For more information on the launch of Manapol, visit the website.
To register for the Los Angeles Super Regional meeting, please visit the event
site.
About Mannatech
Mannatech, Incorporated, develops high-quality health, weight and
fitness, and skin care products that are based on the solid foundation
of nutritional science and development standards. Mannatech is dedicated
to its platform of Social Entrepreneurship based on the foundation of
promoting, aiding and optimizing childhood nutrition where it is needed
most around the world. Mannatech’s proprietary products are available
through independent sales associates around the globe including the
United States, Canada, South Africa, Australia, New Zealand, Austria,
Denmark, Germany, Norway, Sweden, the Netherlands, the United Kingdom,
Japan, Taiwan, Singapore, Estonia, Finland, the Republic of Ireland,
Czech Republic, the Republic of Korea, Mexico, Namibia, Spain and Hong
Kong. For more information, visit Mannatech.com.
Please note: This release contains “forward-looking statements”
within the meaning of Section 27A of the Securities Act of 1933, as
amended, Section 21E of the Securities Exchange Act of 1934, as amended,
and the Private Securities Litigation Reform Act of 1995. These
forward-looking statements generally can be identified by use of phrases
or terminology such as “intend” or other similar words or the negative
of such terminology. Similarly, descriptions of Mannatech’s objectives,
strategies, plans, goals or targets contained herein are also considered
forward-looking statements. Mannatech believes this release should be
read in conjunction with all of its filings with the United States
Securities and Exchange Commission and cautions its readers that these
forward-looking statements are subject to certain events, risks,
uncertainties and other factors. Some of these factors include, among
others, Mannatech’s inability to attract and retain associates and
members, increases in competition, litigation, regulatory changes and
its planned growth into new international markets. Although Mannatech
believes that the expectations, statements and assumptions reflected in
these forward-looking statements are reasonable, it cautions readers to
always consider all of the risk factors and any other cautionary
statements carefully in evaluating each forward-looking statement in
this release, as well as those set forth in its latest Annual Report on
Form 10-K and Quarterly Report on Form 10-Q, and other filings filed
with the United States Securities and Exchange Commission, including its
current reports on Form 8-K. All of the forward-looking statements
contained herein speak only as of the date of this release.
1 The Chemical Abstract Society (CAS) has defined acemannan
as requiring a molecular weight of one million Daltons or more.
*This statement has not been evaluated by the Food and Drug
Administration. This product is not intended to diagnose, treat, cure or
prevent any disease.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150810006314/en/
Source: Mannatech, Incorporated
Mannatech, Incorporated
Raquel Mooring, 972-471-1532
pr@mannatech.com